Noa Biran, MD

Articles

Dr Biran on the IMROZ Trial in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 17th 2024

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Dr Biran on the DREAMM-7 Trial in Multiple Myeloma

July 11th 2024

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Dr Biran on Future Research Directions in Multiple Myeloma

July 8th 2024

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Dr Biran on Current Unmet Needs in Relapsed/Refractory Multiple Myeloma

June 18th 2024

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

Inside the Clinic: JTCC Experts Highlight Pivotal Ongoing Trials in Multiple Myeloma

March 7th 2022

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

December 13th 2021

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma

February 1st 2020

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

December 8th 2019

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

July 11th 2019

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.

Dr. Biran Discusses Treatment Discontinuation in Myeloma

July 13th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

June 14th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Dr. Biran Discusses Doublets Versus Triplets in Myeloma

March 30th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient–Upfront Transplant Versus Maintenance Therapy

December 31st 2015

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

Monoclonal Antibody-Directed Therapies for the Management of Multiple Myeloma

May 11th 2015

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.